Lamotrigine augmentation versus placebo in Serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: A randomized controlled trial

Iranian Journal of Psychiatry

Volumn 11, Issue 2, 2016, Pages 104-114

  Khalkhali, Mohammadrasoul ^a   Aram, Setareh ^a   Zarrabi, Homa ^a   Kafie, Moosa ^b   Heidarzadeh, Abtin ^a  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF GUILAN   (Iran)

Author keywords

Drug augmentation; Lamotrigine; Obsessive compulsive disorder; Serotonin reuptake inhibitors; Treatment resistant

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; LAMOTRIGINE; PLACEBO; SERTRALINE;

ADOLESCENT; ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DSM-IV-TR; ERYTHEMA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIAL; RASH; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TREATMENT RESISTANT DEPRESSION; TREATMENT WITHDRAWAL; WEIGHT GAIN; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

EID: 84988357930     PISSN: 17354587     EISSN: 20082215     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Subramaniam M, Abdin E, Vaingankar JA, Chong SA. Obsessive-compulsive disorder: prevalence, correlates, help-seeking and quality of life in a multiracial Asian population. Soc Psychiatry Psychiatr Epidemiol 2012; 47: 2035-2043
2. Subramaniam M, Soh P, Vaingankar JA, Picco L, Chong SA. Quality of life in obsessive-compulsive disorder: impact of the disorder and of treatment. CNS Drugs 2013; 27: 367-383
3. Seibell PJ, Hollander E. Management of obsessive-compulsive Disorder. F1000Prime Rep. 2014; 1: 6: 68-74
4. Fornaro M. Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Ann Gen Psychiatry 2011; 28: 10.5
5. Bruno A, Mico U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 2012; 26: 1456-1462
6. Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 2013; 16: 557-574
7. Abudy A, Juven-Wetzler A, Zohar J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs 2011; 25: 585-596
8. Bandelow B. The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectr 2008; 13: 37-46
9. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006; 11: 622-632
10. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005; 58: 424-428
11. Naaijen J, Lythgoe DJ, Amiri H, Buitelaar JK, Glennon JC. Fronto-striatal glutamatergic compounds in compulsive and impulsive syndromes: a review of magnetic resonance spectroscopy studies. Neurosci Biobehav Rev 2015; 52: 74-88
12. Wu K, Hanna GL, Rosenberg DR, Arnold PD. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav 2012; 100: 726-735
13. Bhattacharyya S, Chakraborty K. Glutamatergic dysfunction-newer targets for anti-obsessional drugs. Recent Pat CNS Drug Discov 2007; 2: 47-55
14. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006; 3: 69-81
15. Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther 2011; 132: 314-332
16. Goodman WK, Grice DE, Lapidus KA, Coffey BJ. Obsessive-compulsive disorder. Psychiatric Clinics of North America 2014; 37: 257-267
17. Nakamae T. [Novel treatment strategies for refractory patients with obsessive-compulsive disorder]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 2013; 115: 997-1003
18. Grados MA, Specht MW, Sung HM, Fortune D. Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach. Expert Opin Drug Discov 2013; 8: 1515-1527
19. Fineberg NA, Brown A, Reghunandanan S, Pampaloni I. Evidence-basedpharmacotherapy of obsessive-compulsivedisorder.Int J Neuropsychopharmacol 2012; 15: 1173-1191
20. Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007; 17: 761-767
21. Grant PJ, Joseph LA, Farmer CA, Luckenbaugh DA, Lougee LC, Zarate CA, Jr., et al. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology 2014; 39: 1453-1459
22. Bakhla AK, Verma V, Soren S, Sarkhel S , Chaudhury S. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder. Ind Psychiatry J 2013; 22: 149-152
23. Hosenbocus S, Chahal R. Memantine: a review of possible uses in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2013; 22: 166-171
24. Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl) 2013; 228: 633-640
25. Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013; 47: 175-180
26. Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2010; 30: 34-39
27. Egashira N, Shirakawa A, Abe M, Niki T, Mishima K, Iwasaki K, et al. N-acetyl-L-cysteine inhibits marble-burying behavior in mice. J Pharmacol Sci 2012; 119: 97-101
28. Xia J, Du Y, Han J, Liu G , Wang X. D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis. Drug Des Devel Ther 2015; 9: 2101-2117
29. Chasson GS, Buhlmann U, Tolin DF, Rao SR, Reese HE and Rowley T, et al. Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther 2010; 48: 675-679
30. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2011; 72: 716-721
31. Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry. 2013; 74: 675-684
32. Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet 2013; 52: 627-645
33. Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 2000; 34: 527-528
34. Arrojo-Romero M, Tajes Alonso M , de Leon J. Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder. Case Rep Psychiatry 2013; 2013: 1245-1249
35. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, et al. The Yale-Brown Obsessive Compulsive Scale II. Validity Arch Gen Psychiatry 1989; 46:1006-1011
36. Poyurovsky M, Glick I, Koran LM. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J Psychopharmacol 2010; 24: 861-866
37. Zavodnick AD, Ali R.Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review. Psychiatr Q 2012; 83: 371-383
38. Afshar H, Akuchekian SH, Ahaky B, Zarean E. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. J Res Med Sci2014; 19: 976-981
39. Damien F, Ted K , Franklin M, Fabrizio B. Placebo Effects: Biological, Clinical and Ethical Advances. Lancet 2010; 375: 686-695
40. Wang XQ, Xiong J, Xu WH, Yu SY, Huang XS, Zhang JT, et al. Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis. Seizure 2015; 25: 52-61
41. Pallanti S, Grassi G. Pharmacologic treatment of obsessive-compulsive disorder comorbidity .Expert Opin Pharmacother 2014; 15: 2543-2552
42. Woody E, Szechtman H. Motivation, time course, and heterogeneity in obsessive-compulsive disorder. Psychological Review 2005; 112: 658-661
43. Watson HJ, Rees CS. Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. J Child Psychol Psychiatry 2008; 49: 489-498
44. Bandelow B. The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectr 2008; 13: 37-46
45. Amerio A, Stubbs B, Odone A, Tonna M, Marchesi C , Ghaemi SN. The prevalence and predictors of comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review and meta-analysis. J Affect Disord 2015; 186: 99-109
46. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194: 4-9
47. Jeong JH, Lee JG, Kim MD, Sohn I, Shim SH, Wang HR, et al. Korean Medication Algorithm for Bipolar Disorder 2014: comparisons with other treatment guidelines. Neuropsychiatr Dis Treat 2015; 11: 1561-1571
48. Wang HR, Woo YS, Bahk WM. Anticonvulsants to treat post-traumatic stress disorder. Hum Psychopharmacol 2014; 29: 427-433